

VentriPoint Diagnostics Ltd.

09:00 15 May 2019

Ventripoint Diagnostics to bring its cardiac-imaging technology to France

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) on Wednesday announced it has signed an authorized sales agent agreement with Irudigi to bring its cardiac-imaging technology to France.

Irudigi, based in France, is a medical imaging and health-care information technology company. Under the sales agreement, Irudigi will help bring to market Ventripoint's VMS+ device that uses artificial intelligence to streamline volumetric measurements of all four heart chambers with conventional ultrasound, according to a statement.

"Irudigi's knowledge of the cardiac market in France and experience within the imaging industry will be an asset to the business as we continue to grow," said Ventripoint CEO George Adams.

READ: Ventripoint Diagnostics to advance AI capabilities in its heart device with new gov't funding

Irudigi CEO Pierre Zavattero said that France lacks magnetic resonance imaging (MRI) scanners, which heightens the need for Ventripoint's technology.

"There are over 1 million people suffering from cardiac impairments in France, a number that grew by 30% over the last decade," he said. "The combination of low MRI coverage, a growing number of patients, and financial incentives make the Ventripoint VMS+ a perfectly suited solution for the French market."

Ventripoint, based on Toronto, noted in its statement that neighbors Germany, Italy and Spain have at least twice as many MRIs than France. Consequently, current waiting times for MRIs are over a month in France, while they are only 1 to 2 weeks for echography, with a significantly shorter examination time, the company added.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential,

Price: C\$0.14

Market Cap: C\$8170910M

1 Year Share Price Graph



Share Information

Code: VPT

Listing: TSX-V

52 week High Low
C\$0.27 C\$0.10

Sector: Health Care, Equipment & Services [T3]

Website: www.ventripoint.com

Company Synopsis:

Ventripoint (TSXV: VPT) has redesigned VMS to meet the demands of every market. Preparing to move beyond the Left and Right Ventricle to become the first platform to offer 3D volumes for all cardiac chambers, with accuracy equivalent to MRI. all from the convenience of 2D Ultrasound.

action@proactiveinvestors.com

advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.